Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
As of Nov 16, 2026, ANDA 212779 (Potassium Citrate), held by Ani Pharms, was first approved by FDA on Jan 14, 2020, with 1 approved supplement and 0 published complete response letters.
First approved: Jan 14, 2020
Review: Standard
Supplements approved: 1
Complete response letters: 0
What It's For
From the FDA-approved label (Indications and Usage)
Potassium Citrate Extended-Release Tablets are a citrate salt of potassium indicated for the management of:
Renal tubular acidosis (RTA) with calcium stones
Hypocitraturic calcium oxalate nephrolithiasis of any etiology
Uric acid lithiasis with or without calcium stones 1.1 Renal Tubular Acidosis (RTA) with Calcium Stones Potassium citrate is indicated for the management of renal tubular acidosis. 1.2 Hypocitraturic Calcium Oxalate Nephrolithiasis of any Etiology Potassium citrate is indicated for the management of hypocitraturic calcium oxalate nephrolithiasis. 1.
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters.Drugs@FDA and FDA complete response letters